10月23日，康为世纪涨5.5%，截至发稿，报28.79元/股，成交4491.93万元，换手率4.24%，总市值32.39 亿元。 资料显示，江苏康为世纪生物科技股份有限公司位于江苏省泰州市医药高新区泽兰路18号，成立日期 2010年9月3日，上市日期2022年10月25日，公司主营业务涉及分子检测产品的研发、生产和销售,并提 供分子检测服务。主营业务收入构成为：销售商品89.14%，提供服务10.86%，其他(补充)0.00%。 申万菱信医药先锋股票A（005433）成立日期2020年11月16日，最新规模1.2亿。今年以来亏损7%，同 类排名4215/4218；近一年亏损10.41%，同类排名3867/3875；成立以来亏损49.92%。 申万菱信医药先锋股票A（005433）基金经理为姚宏福。 截至发稿，姚宏福累计任职时间3年98天，现任基金资产总规模1.33亿元，任职期间最佳基金回 报-31.23%， 任职期间最差基金回报-32.27%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考， ...

Core Viewpoint - 康为世纪's stock price decreased by 0.82% on October 10, with a trading volume of 47.09 million yuan, indicating a potential market reaction to recent financial performance and investor sentiment [1] Financing Summary - On October 10, 康为世纪 had a financing buy-in amount of 6.84 million yuan, with a net financing purchase of 2.75 million yuan, reflecting strong investor interest [1] - The total financing balance reached 116 million yuan, accounting for 11.05% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of leverage [1] - No short selling activity was recorded on October 10, with a short selling balance of 0 yuan, also reflecting a high percentile position over the past year [1] Financial Performance - For the first half of 2025, 康为世纪 reported a revenue of 87.12 million yuan, representing a year-on-year growth of 29.74%, indicating strong sales performance [2] - The company experienced a net loss attributable to shareholders of 55.91 million yuan, which is a decrease of 11.70% compared to the previous period, highlighting ongoing profitability challenges [2] Shareholder and Dividend Information - Since its A-share listing, 康为世纪 has distributed a total of 48.63 million yuan in dividends [3] - As of June 30, 2025, the number of shareholders increased by 0.25% to 3,949, while the average number of circulating shares per person decreased by 0.25% to 9,621 shares [2][3] - The largest circulating shareholder is 融通健康产业灵活配置混合A/B, holding 3.60 million shares, which decreased by 16,120 shares compared to the previous period [3]

9月23日，康为世纪盘中下跌2.05%，截至09:38，报26.32元/股，成交234.57万元，换手率0.23%，总市 值29.61亿元。 康为世纪所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基金重仓、融资融券、 小盘、医疗器械、体外诊断等。 截至6月30日，康为世纪股东户数3949.00，较上期增加0.25%；人均流通股9621股，较上期减少0.25%。 2025年1月-6月，康为世纪实现营业收入8711.87万元，同比增长29.74%；归母净利润-5591.11万元，同 比减少11.70%。 分红方面，康为世纪A股上市后累计派现4863.19万元。 机构持仓方面，截止2025年6月30日，康为世纪十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第一大流通股东，持股360.00万股，相比上期减少16.12万股。中欧时代先锋股票A （001938）位居第三大流通股东，持股200.00万股，为新进股东。圆信永丰医药健康A（006274）位居 第七大流通股东，持股67.28万股，相比上期增加9.18万股。圆信永丰聚优A（010469）位居第八大流通 股东，持股66.00万 ...

Group 1 - The core viewpoint of the news is that Kangwei Century's stock has experienced a decline of 5.09% on September 17, with a total market value of 3.124 billion yuan and a cumulative drop of 3.94% over three consecutive days [1] - Kangwei Century, established on September 3, 2010, specializes in the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales and 10.86% from services [1] - The stock trading volume on the reporting day was 41.74 million yuan, with a turnover rate of 3.87% [1] Group 2 - Among the top ten circulating shareholders of Kangwei Century, a fund under China Europe Fund, specifically the China Europe Times Pioneer Stock A (001938), has entered the list, holding 2 million shares, which accounts for 5.26% of the circulating shares [2] - The fund has incurred a floating loss of approximately 2.98 million yuan today, with a total floating loss of 2.4 million yuan during the three-day decline [2] - The fund manager, Zhou Weiwen, has a tenure of 18 years and 312 days, with a total fund asset scale of 29.38 billion yuan, while the other manager, Luo Jiaming, has a tenure of 6 years and 80 days, managing assets of 13.271 billion yuan [2]

Group 1 - The stock price of Kangwei Century has increased by 5.23% on September 11, reaching 31.00 CNY per share, with a trading volume of 96.66 million CNY and a turnover rate of 8.51%, resulting in a total market capitalization of 3.487 billion CNY [1] - Kangwei Century's stock has risen for three consecutive days, with a cumulative increase of 20.89% during this period [1] - The company, established on September 3, 2010, specializes in the research, production, and sales of molecular detection products, providing molecular detection services as well [1] Group 2 - According to data, one fund from Shenwan Lingxin has Kangwei Century as a top holding, with a reduction of 12,000 shares in the second quarter, holding 445,600 shares, which accounts for 7.43% of the fund's net value, making it the second-largest holding [2] - The fund, Shenwan Lingxin Medical Pioneer Stock A (005433), has a current scale of 120 million CNY and has achieved a return of 5.11% this year, ranking 3885 out of 4222 in its category [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 56 days, with the best fund return during his tenure being -23.62% and the worst being -24.59% [2]